An orthotopic syngeneic mouse model of bortezomib-resistant multiple myeloma
Files
(Published version)
Date
2024
Authors
Li, M.
Bennett, M.K.
Toubia, J.
Pope, V.S.
Tea, M.N.
Tamang, S.
Samuel, M.S.
Anderson, P.H.
Gliddon, B.L.
Powell, J.A.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
British Journal of Haematology, 2024; 204(2):566-570
Statement of Responsibility
Manjun Li, Melissa K. Bennett, John Toubia, Victoria S. Pope, Melinda N. Tea, Sarah Tamang, Michael S. Samuel, Paul H. Anderson, Briony L. Gliddon, Jason A. Powell, Stuart M. Pitson
Conference Name
Abstract
While bortezomib has significant benefits in multiple myeloma (MM) therapy, the disease remains incurable due to the invariable development of bortezomib resistance. This emphasises the need for advanced models for preclinical evaluation of new therapeutic approaches for bortezomib-resistant MM. Here, we describe the development of an orthotopic syngeneic bortezomib-resistant MM mouse model based on the most well-characterised syngeneic MM mouse model derived from spontaneous MM-forming C57BL/KaLwRij mice. Using bortezomib-resistant 5TGM1 cells, we report and characterise a robust syngeneic mouse model of bortezomib-resistant MM that is well suited to the evaluation of new therapeutic approaches for proteasome inhibitor-resistant MM.
School/Discipline
Dissertation Note
Provenance
Description
Data source: Supporting information, https://doi.org/10.1111/bjh.19240
Access Status
Rights
© 2023 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.